ABSTRACT
Spinal cord injury (SCI) is still a major challenge for translational medicine. Polylaminin is a stabilized form of laminin, a natural multifunctional protein, previously shown to promote neuroprotection and axonal growth after SCI in rodents. Here we present the results of a confirmatory preclinical study performed in rats and of a first in human trial of polylaminin to treat acute SCI. The latter was an open-label, single-armed academic study designed to include only patients diagnosed with functional complete SCI, because no more than 15% of these patients recover motor function spontaneously. Eight participants received a single intraspinal injection of polylaminin shortly after trauma (average time = 2.3 days). Two died within the first days of causes related to the gravity of the condition. The six patients that survived to reach the one-month follow-up were evaluated using the International Standards for Neurological Classification of Spinal Cord Injury (6/6) and motor and somatosensory evoked potentials (3/6). All the six patients regained voluntary motor control below the level of the lesion, which is an unprecedented recovery. This preliminary study suggests the efficacy of polylaminin to treat acute SCI, revealing its potential as a new therapy to restore motor function to paralyzed people (UTN: U1111-1144-5390).
Competing Interest Statement
Tatiana Coelho-Sampaio is a consultant to Cristalia Laboratory. The other authors have no competing interests to report.
Clinical Trial
U1111-1144-5390
Funding Statement
This work was supported by Rio de Janeiro State Science Foundation (FAPERJ), grant number E-26/111.302/2013
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This trial was approved by the National Commission of Ethics in Medical Research (CONEP), Brazil, CAAE 3.474.884, and retrospectively registered in the Brazilian National Clinical Trials Registry under the Universal Trial Number (UTN), U1111-1144-5390
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
